# PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

> **NCT04983901** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Imipenem/Cilastatin/Relebactam
- **DRUG:** Cefepime
- **DRUG:** Meropenem
- **DRUG:** Piperacillin-Tazobactam
- **DRUG:** Vancomycin
- **DRUG:** Daptomycin
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT04983901
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-10-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983901, "PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04983901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*